News
The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback